Cardio Diagnostics Holdings, Inc. (CDIO) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Cardio Diagnostics Holdings, Inc. (CDIO) stock forecast summary
On Oct. 13, 2026, CDIO is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Cardio Diagnostics Holdings, Inc. is a small-cap company with a market capitalization of $5M. It ranks number 14 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its ROE of -87.1% is the lowest of the 11 peers that report one. Its Current Ratio of 17.15x is the highest of the 15 peers that report one.
A per-ticker accuracy statistic for CDIO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CDIO included.
Follow CDIO freeCDIO price chart and AI forecast
How CDIO ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cardio Diagnostics Holdings, Inc. (CDIO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | CDIO | Rank |
|---|---|---|
| Market Cap | $5M | 14/15 |
| P/B Ratio | 0.71x | 10/11 |
| EPS | $-3.25 | – |
| Book Value/Share | $2.51 | – |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-1.97 | – |
Profitability & Margins
| Metric | CDIO | Rank |
|---|---|---|
| ROE | -87.1% | 11/11 |
| ROA | -81.6% | 12/13 |
| ROIC | -85.3% | 11/11 |
| Operating Margin | -44690.7% | 13/14 |
| Net Margin | -44771.8% | 10/11 |
| EBT Margin | -44771.8% | 13/14 |
Financial Health
| Metric | CDIO | Rank |
|---|---|---|
| Current Ratio | 17.15x | 1/15 |
| D/E Ratio | 0.07x | 12/12 |
| Financial Leverage | 1.07x | 12/12 |
| Interest Coverage | -435.5x | 13/14 |
| Working Capital | $6M | 12/15 |
Cash Flow
| Metric | CDIO | Rank |
|---|---|---|
| Operating Cash Flow | -$6M | 8/16 |
| Free Cash Flow | -$6M | 4/10 |
| Capital Spending | -$160K | 2/10 |
| FCF/Sales | -40307.5% | 9/10 |
| CapEx/Sales | 1139.1% | 2/10 |
Operational Efficiency
| Metric | CDIO | Rank |
|---|---|---|
| Asset Turnover | 0.00x | 11/12 |
| Receivables Turnover | 3.7x | 11/11 |
| Fixed Assets Turnover | 0.0x | 11/12 |
| Days Sales Outstanding | 99 days | 1/11 |
Income Statement
| Metric | CDIO | Rank |
|---|---|---|
| Total Revenue | $0.00M | 11/12 |
| Operating Income | -$6M | 5/15 |
| Net Income | -$6M | 4/13 |
| R&D Expense | $770K | 16/16 |
| SG&A Expense | $6M | 11/12 |
Dividend & Shareholder Information
| Metric | CDIO | Rank |
|---|---|---|
| Shares Outstanding | 3M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $6M | 77.8% of assets |
| Cash & Short-term Investments | $0.00M | 0.0% of assets |
| Accounts Receivable | $0.00M | 0.0% of assets |
| Total Liabilities | $500K | 6.3% of assets |
CDIO quarterly financials and insider trading
Cardio Diagnostics Holdings, Inc. (CDIO) industry peers
Companies classified under the same SEC industry code as Cardio Diagnostics Holdings, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| BMRA Biomerica Inc | ▲ | $8M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Where CDIO sits on the market map
Cardio Diagnostics Holdings, Inc. (CDIO) stock news
Loading...
Cardio Diagnostics Holdings, Inc. (CDIO) stock forecast FAQ
What is the Cardio Diagnostics Holdings, Inc. (CDIO) stock forecast?
On Oct. 13, 2026, CDIO is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Cardio Diagnostics Holdings, Inc. stock predictions?
A per-ticker accuracy statistic for CDIO is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cardio Diagnostics Holdings, Inc. forecasts updated?
Cardio Diagnostics Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Cardio Diagnostics Holdings, Inc.'s industry peers?
17 issuers in our coverage, CDIO included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.